CSI Market
Sign In | Register

First China Pharmaceutical Group (FCPG) Annual Income Statement

Annual · GAAP · USD millions
Access FCPG quarterly income statements →
Income statement data covering First China Pharmaceutical Group– offers a view into how Mar 31 2010's operating results have moved alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Mar 31 2010)
2011
Revenues
Total Revenue25.72
Costs & Expenses
Cost of Goods and Services Sold21.05
Gross Profit0.00
Selling, Administration, Marketing0.96
Depreciation & Amortization0.01
Total operating costs including COS22.00
Operating income / -loss3.72
Net Interest (-)Expense / Income-0.06
Loss / -Gain on Investment0.01
Foreign Currency Transaction Gain (Loss), before Tax0.02
Total costs & expenses0.00
Income & Taxes
Income / -loss before income taxes3.70
Income taxes expenses / -benefit0.93
Income after income taxes2.76
Income / -loss from continuing operations2.76
Net income / -loss2.76
Income / -loss to shareholder0.78
EBIT3.76
EBITD3.76
EBITDA3.77
Earnings Per Share
Basic EPS (excl. extra items)0.02
Basic Net EPS0.02
Basic shares outstanding (Mill. of Units)51.25
Diluted Net EPS0.02
Diluted average shares (Mill. of Units)51.39
4 historic quarters locked

Sign in to unlock the full First China Pharmaceutical Group income statement history.

Sign In Create Free Account

About FCPG Annual Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-K filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-K filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API Connect Your AI